- Home
- XMTR vs APLT Comparison
XMTR vs APLT Comparison
Compare XMTR & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- APLT
- Stock Information
- Founded
- XMTR 2013
- APLT 2016
- Country
- XMTR United States
- APLT United States
- Employees
- XMTR N/A
- APLT N/A
- Industry
- XMTR Industrial Machinery/Components
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- APLT Health Care
- Exchange
- XMTR Nasdaq
- APLT Nasdaq
- Market Cap
- XMTR 1.0B
- APLT 128.0M
- IPO Year
- XMTR 2021
- APLT 2019
- Fundamental
- Price
- XMTR $41.63
- APLT $0.90
- Analyst Decision
- XMTR Buy
- APLT Buy
- Analyst Count
- XMTR 9
- APLT 7
- Target Price
- XMTR $33.63
- APLT $6.10
- AVG Volume (30 Days)
- XMTR 665.1K
- APLT 8.4M
- Earning Date
- XMTR 02-27-2025
- APLT 11-07-2024
- Dividend Yield
- XMTR N/A
- APLT N/A
- EPS Growth
- XMTR N/A
- APLT N/A
- EPS
- XMTR N/A
- APLT N/A
- Revenue
- XMTR $525,128,000.00
- APLT N/A
- Revenue This Year
- XMTR $19.60
- APLT N/A
- Revenue Next Year
- XMTR $19.06
- APLT $2,664.24
- P/E Ratio
- XMTR N/A
- APLT N/A
- Revenue Growth
- XMTR 21.19
- APLT N/A
- 52 Week Low
- XMTR $11.08
- APLT $0.77
- 52 Week High
- XMTR $45.33
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- XMTR 68.87
- APLT 19.46
- Support Level
- XMTR $35.46
- APLT $0.78
- Resistance Level
- XMTR $45.33
- APLT $0.90
- Average True Range (ATR)
- XMTR 2.87
- APLT 0.12
- MACD
- XMTR 0.17
- APLT 0.26
- Stochastic Oscillator
- XMTR 69.62
- APLT 20.97
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of the revenue is earned from the U.S. segment.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.